Home  |  About the Book  |  Table of Contents  |  Search  |  Order  |  Visit JCO  |  Visit ASCO.org
ASCO Educational Book; 2008
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar content in this book
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Turcotte, S.
Right arrow Articles by Giaccia, A. J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Turcotte, S.
Right arrow Articles by Giaccia, A. J.

Targeted Therapy for the Loss of the Tumor Suppressor Gene von Hippel-Lindau through Synthetic Lethality

Sandra Turcotte, PhD, and Amato J. Giaccia, PhD

From the Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA

Authors’ disclosures of potential conflicts of interest are found at the end of this article.

Address reprint requests to Amato J. Giaccia, PhD, Department of Radiation Oncology, Stanford University School of Medicine, 801 Welch Road, Stanford, CA 94305; e-mail: giaccia{at}stanford.edu

Overview: This review focuses on novel approaches in cancer treatment as targeted therapies and synthetic lethality. We present recent advances in HIF-targeted therapy and discuss the feasibility of targeting the loss of the tumor suppressor gene von Hippel-Lindau for the treatment of renal cell carcinoma using small molecules.